Résultats de la recherche - Vincenzo Libri

Affiner les résultats
  1. 1
    Evidence that locus coeruleus is the site where clonidine and drugs acting at α<sub>1</sub>‐ and α<sub>2</sub>‐adrenoceptors affect sleep and arousal mechanisms

    Evidence that locus coeruleus is the site where clonidine and drugs acting at α<sub>1</sub>‐ and α<sub>2</sub>‐adrenoceptors affect sleep and arousal mechanisms par Giovambattista De Sarro, C. Ascioti, F. Froio, Vincenzo Libri, Giuseppe Nisticò

    Publié 1987
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  2. 2
    PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis

    PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis par Andrew Lockhart, Janette Lamb, Tracy Osredkar, Lucia I. Sue, Jeffrey N. Joyce, L. Ye, Vincenzo Libri, David Leppert, Thomas G. Beach

    Publié 2007
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  3. 3
    Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies

    Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies par Paul Thompson, Liang Ye, Jennifer L. Morgenstern, Lucia I. Sue, Thomas G. Beach, Duncan J. Judd, Nicholas J. Shipley, Vincenzo Libri, Andrew Lockhart

    Publié 2009
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  4. 4
    <i>In vitro</i> high affinity α‐synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain<sup>1</sup>

    <i>In vitro</i> high affinity α‐synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain<sup>1</sup> par Liang Ye, Ana Luisa Velasco, Graham Fraser, Thomas G. Beach, Lucia I. Sue, Tracy Osredkar, Vincenzo Libri, Maria Grazia Spillantini, Michel Goedert, Andrew Lockhart

    Publié 2008
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  5. 5
    A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers

    A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers par Vincenzo Libri, Andrew Brown, Giulio Gambarota, Jonathan Haddad, Gregory S Shields, Helen Dawes, David J. Pinato, Ethan Hoffman, Peter Elliot, George P. Vlasuk, Eric Jacobson, Martin R. Wilkins, Paul M. Matthews

    Publié 2012
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  6. 6
    Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18 F-FDG) PET in Patients With Alzheimer Disease, Mild Cognitive Impairment, and Healthy Controls

    Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18 F-FDG) PET in Patients With Alzheimer Disease, Mild Cognitive Impairment, and Healthy Controls par Davangere P. Devanand, Arthur Mikhno, Gregory H. Pelton, Katrina Cuasay, Gnanavalli Pradhaban, J.S. Dileep Kumar, Neil Upton, Robert Lai, Roger N. Gunn, Vincenzo Libri, Xinhua Liu, Ronald Van Heertum, J. John Mann, Ramin V. Parsey

    Publié 2010
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  7. 7
    Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study

    Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study par Vincenzo Libri, Cihangir Yandım, Stavros Athanasopoulos, Naomi Loyse, Theona Natisvili, Pui Pik Law, Ping Kei Chan, Tariq Mohammad, Marta Mauri, Kin Tung Tam, James Leiper, Sophie Piper, Aravind Ramesh, Michael Parkinson, Les Huson, Paola Giunti, Richard Festenstein

    Publié 2014
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  8. 8
    Determination of [<sup>11</sup>C]PBR28 Binding Potential <i>in vivo:</i> A First Human TSPO Blocking Study

    Determination of [<sup>11</sup>C]PBR28 Binding Potential <i>in vivo:</i> A First Human TSPO Blocking Study par David R. Owen, Qi Guo, Nicola J. Kalk, Alessandro Colasanti, Dimitra Kalogiannopoulou, Rahul Dimber, Yvonne Lewis, Vincenzo Libri, Julien Barletta, Joaquim Ramada‐Magalhaes, Aruloly Kamalakaran, David Nutt, Jan Passchier, Paul M. Matthews, Roger N. Gunn, Eugenii A. Rabiner

    Publié 2014
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  9. 9
    <i>TSPO</i> mutations in rats and a human polymorphism impair the rate of steroid synthesis

    <i>TSPO</i> mutations in rats and a human polymorphism impair the rate of steroid synthesis par David R. Owen, Jinjiang Fan, Enrico Campioli, Sathvika Venugopal, Andrew Midzak, Edward Daly, A Harlay, Leeyah Issop, Vincenzo Libri, Dimitra Kalogiannopoulou, Eduardo Oliver, Enrique Gallego-Colón, Alessandro Colasanti, Les Huson, Eugenii A. Rabiner, Puvan Suppiah, Charles Essagian, Paul M. Matthews, Vassilios Papadopoulos

    Publié 2017
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  10. 10
    Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations

    Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations par Stephen Mullin, Laura Smith, Katherine Lee, Gayle D’Souza, Philip Woodgate, Josh Elflein, Jenny Hällqvist, Marco Toffoli, Adam Streeter, Joanne Hosking, Wendy Heywood, Rajeshree Khengar, Philip Campbell, Jason Hehir, Sarah Cable, Kevin Mills, Henrik Zetterberg, Patricia Limousin, Vincenzo Libri, Thomas Foltynie, Anthony H.V. Schapira

    Publié 2020
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  11. 11
    Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme

    Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme par Simon Mead, Azadeh Khalili-Shirazi, Caroline Potter, Tzehow Mok, Akın Nihat, Harpreet Hyare, Stephanie Canning, Christian Schmidt, Tracy Campbell, Lee Darwent, Nicola Muirhead, Nicolette M. Ebsworth, Patrick Hextall, Madeleine Wakeling, Jacqueline M. Linehan, Vincenzo Libri, Bryan Williams, Zane Jaunmuktane, Sebastian Brandner, Peter Rudge, John Collinge

    Publié 2022
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  12. 12
    A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (<scp>UDCA)</scp> in Parkinson's Disease

    A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (<scp>UDCA)</scp> in Parkinson's Disease par Thomas Payne, Matthew Appleby, Ellen Buckley, Linda Van Gelder, Benjamin H. Mullish, Matilde Sassani, Mark Dunning, Dena Hernández, Sonja W. Scholz, Alisdair McNeill, Vincenzo Libri, Sarah Moll, Julian R. Marchesi, Rosie Taylor, Li Su, Claudia Mazzà, Thomas M. Jenkins, Thomas Foltynie, Oliver Bandmann

    Publié 2023
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  13. 13
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign

    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign par Marianne Shawe‐Taylor, David Greenwood, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, Vincenzo Libri, George Kassiotis, S.J. Gamblin, Nicola S. Lewis, Bryan Williams, Charles Swanton, Sonia Gandhi, Edward J Carr, Mary Wu, David L.V. Bauer, Emma Wall

    Publié 2024
    Accéder au texte intégral
    Carta
    Ajouter aux favoris
    Enregistré dans:
  14. 14
    AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

    AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC par Emma Wall, Mary Wu, Ruth Harvey, Gavin Kelly, Scott Warchal, Chelsea Sawyer, Rodney S. Daniels, Lorin Adams, Philip Hobson, Emine Hatipoglu, Yenting Ngai, Saira Hussain, Karen Ambrose, Steve Hindmarsh, Rupert Beale, Andrew Riddell, Steve Gamblin, Michael Howell, George Kassiotis, Vincenzo Libri, Bryan Williams, Charles Swanton, Sonia Gandhi, David L.V. Bauer

    Publié 2021
    Accéder au texte intégral
    Carta
    Ajouter aux favoris
    Enregistré dans:
  15. 15
    Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

    Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination par Emma Wall, Mary Wu, Ruth Harvey, Gavin Kelly, Scott Warchal, Chelsea Sawyer, Rodney S. Daniels, Philip Hobson, Emine Hatipoglu, Yenting Ngai, Saira Hussain, Jérôme Nicod, Robert Goldstone, Karen Ambrose, Steve Hindmarsh, Rupert Beale, Andrew Riddell, Steve Gamblin, Michael Howell, George Kassiotis, Vincenzo Libri, Bryan Williams, Charles Swanton, Sonia Gandhi, David L.V. Bauer

    Publié 2021
    Accéder au texte intégral
    Carta
    Ajouter aux favoris
    Enregistré dans:
  16. 16
    Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

    Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo... par Nirosen Vijiaratnam, Christine Girges, Grace Auld, Marisa Chau, Kate Maclagan, Alexa King, Simon S. Skene, Kashfia Chowdhury, Steve Hibbert, Huw R. Morris, Patricia Limousin, Dilan Athauda, Camille Carroll, Joshua Shulman, Monty Silverdale, Gordon W. Duncan, К. Ray Chaudhuri, Christine Lo, Silvia Del Din, Alison J. Yarnall, Lynn Rochester, Rachel Gibson, John Dickson, Rachael Hunter, Vincenzo Libri, Thomas Foltynie

    Publié 2021
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  17. 17
    Three-dose vaccination elicits neutralising antibodies against omicron

    Three-dose vaccination elicits neutralising antibodies against omicron par Mary Wu, Emma Wall, Edward J Carr, Ruth Harvey, Hermaleigh Townsley, Harriet V Mears, Lorin Adams, Svend Kjær, Gavin Kelly, Scott Warchal, Chelsea Sawyer, Caitlin Kavanagh, Christophe J. Queval, Yenting Ngai, Emine Hatipoglu, Karen Ambrose, Steve Hindmarsh, Rupert Beale, Steve Gamblin, Michael Howell, George Kassiotis, Vincenzo Libri, Bryan Williams, Sonia Gandhi, Charles Swanton, David L.V. Bauer

    Publié 2022
    Accéder au texte intégral
    Carta
    Ajouter aux favoris
    Enregistré dans:
  18. 18
    COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

    COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2 par Alex J. Szubert, Katrina M. Pollock, Hannah M. Cheeseman, Jasmini Alagaratnam, Henry Bern, Olivia Bird, Marta Boffito, Ruth A. Byrne, Tom Cole, Catherine A. Cosgrove, Saul N. Faust, Sarah Fidler, Eva Galiza, Hana Hassanin, Mohini Kalyan, Vincenzo Libri, Leon R. McFarlane, Ana Milinkovic, Jessica O’Hara, David R. Owen, DR Owens, Mihaela Pacurar, Tommy Rampling, Simon S. Skene, Alan Winston, James Woolley, Yee Ting Nicole Yim, David Dunn, Sheena McCormack, Robin J. Shattock

    Publié 2023
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  19. 19
    Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection

    Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection par Edward J Carr, Mary Wu, Joshua Gahir, Ruth Harvey, Hermaleigh Townsley, Chris Bailey, Ashley S Fowler, Giulia Dowgier, Agnieszka Hobbs, Lou Herman, Martina Ragno, Murad Miah, Phillip Bawumia, Callie Smith, Mauro Miranda, Harriet V Mears, Lorin Adams, Emine Haptipoglu, Nicola O’Reilly, Scott Warchal, Chelsea Sawyer, Karen Ambrose, Gavin Kelly, Rupert Beale, Padmasayee Papineni, Tumena Corrah, Richard Gilson, Steve Gamblin, George Kassiotis, Vincenzo Libri, Bryan Williams, Charles Swanton, Sonia Gandhi, David L.V. Bauer, Emma Wall

    Publié 2023
    Accéder au texte intégral
    Carta
    Ajouter aux favoris
    Enregistré dans:
  20. 20
    Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

    Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group,... par Nirosen Vijiaratnam, Christine Girges, Grace Auld, Rachel McComish, Alexa King, Simon S. Skene, Steve Hibbert, Alan Wong, Sabina Melander, Rachel Gibson, Helen Matthews, John Dickson, Camille Carroll, Abigail Patrick, Jemma Inches, Monty Silverdale, Bethan Blackledge, Jessica Whiston, Joshua Shulman, Jessica Welch, Gordon W. Duncan, Kevin Power, Sarah Gallen, Jacqueline Kerr, К. Ray Chaudhuri, Lucia Batzu, Silvia Rota, Edwin Jabbari, Huw R. Morris, Patricia Limousin, Nigel H. Greig, Yazhou Li, Vincenzo Libri, Sonia Gandhi, Dilan Athauda, Kashfia Chowdhury, Thomas Foltynie

    Publié 2025
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:

Outils de recherche: